ResearcherTottori UniversityActive in the last 2 years
Mikiya Kishino
Matched on OpenAlex author ID A5111211585. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 4, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2024: 3 papers · 2025: 1 paper · 2026: 4 papers
Papers 8
- The interactions between geriatric nutritional risk index and systemic immune-inflammation index for post-recurrence prognosis in patients with pancreatic canc… Co-author DOI 10.1186/s12957-026-04370-y↗
- Impact of CD73+CD39+ B Cells on Immune Evasion in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.18437↗
- The Clinical Impact of Prognostic Nutritional Index at Recurrence of Pancreatic Cancer. Co-author DOI 10.21873/cdp.10573↗
- Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent Pancreatic Cancer. Co-author DOI 10.21873/invivo.14436↗
- Prognostic Relationship Between the Cachexia Index and Osteopenia in Patients With Pancreatic Cancer. First author DOI 10.21873/anticanres.17509↗
- The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer. First author DOI 10.1007/s00595-024-02877-z↗
- Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenoca… First author DOI 10.1016/j.hpb.2024.03.603↗
- Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenoca… First author DOI 10.1097/md.0000000000038292↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Teruhisa Sakamoto · 8 shared papers, 2024–2026 · strength 1.88
- Paper The Clinical Impact of Prognostic Nutritional Index at Recurrence of Pancreatic Cancer. DOI 10.21873/cdp.10573↗
- Paper The interactions between geriatric nutritional risk index and systemic immune-inflammation index for post-recurrence pr… DOI 10.1186/s12957-026-04370-y↗
- Paper Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent… DOI 10.21873/invivo.14436↗
- Masaki Morimoto · 4 shared papers, 2026 · strength 1.03
- Paper The Clinical Impact of Prognostic Nutritional Index at Recurrence of Pancreatic Cancer. DOI 10.21873/cdp.10573↗
- Paper The interactions between geriatric nutritional risk index and systemic immune-inflammation index for post-recurrence pr… DOI 10.1186/s12957-026-04370-y↗
- Paper Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent… DOI 10.21873/invivo.14436↗
- Yoshiyuki Fujiwara · 3 shared papers, 2024–2025 · strength 0.65
- Paper Prognostic Relationship Between the Cachexia Index and Osteopenia in Patients With Pancreatic Cancer. DOI 10.21873/anticanres.17509↗
- Paper The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer. DOI 10.1007/s00595-024-02877-z↗
- Paper Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival afte… DOI 10.1016/j.hpb.2024.03.603↗
- Takehiko Hanaki · 3 shared papers, 2024 · strength 0.60
- Paper The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer. DOI 10.1007/s00595-024-02877-z↗
- Paper Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival afte… DOI 10.1016/j.hpb.2024.03.603↗
- Paper Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival afte… DOI 10.1097/md.0000000000038292↗
- Yoshiyuki Fujiwara · 2 shared papers, 2026 · strength 0.53
- Yoshiyuki Fujiwara · 2 shared papers, 2024–2026 · strength 0.43
- Yuki Murakami · 2 shared papers, 2024 · strength 0.40
- Yoshiyuki Fujiwara · 1 shared paper, 2026 · strength 0.26
- Takuki Yagyu · 1 shared paper, 2026 · strength 0.23
- Yoshihisa Umekita · 1 shared paper, 2026 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.